Lumexa Imaging
LMRI
10.24
-0.35
-3.31%
Lumexa Imaging
US · LMRI
#3235 by market cap
Listed 2025
10.24
-0.35
-3.31%
Live - 5344 symbols - heartbeat 267s ago
· 2026-10-08 09:55
Pre-market
10.56
-0.28%
After-hours
10.59
0.00%
- Market cap
- 983.81M
- P/E (TTM)i
- -35.43
- P/Bi
- 1.60
- EPSi
- -0.49
- Div yieldi
- 0.00%
- 52W posi
- 29%
Reader sentiment
Are you bullish or bearish on LMRI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.66, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 3 years
Latest year +7.82% YoY
Margins
- Gross margin
- 15.40%
- Operating margin
- 2.61%
- Net margin
- -4.60%
Key ratios & quality
- Enterprise valuei
- 1.78B
- Altman Z-Scorei
- 0.66
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 935.93M | 948.87M | 1.02B |
| Gross profit | 98.97M | 96.26M | 157.57M |
| Selling & admin expenses | 55.17M | 70.36M | 90.45M |
| Research & development | -- | -- | -- |
| Operating profit | -12.83M | -16.26M | 26.73M |
| Pretax profit | -119.25M | -79.19M | -32.22M |
| Tax | 2.98M | 14.91M | 14.89M |
| Net profit | -122.23M | -94.10M | -47.10M |
| Basic EPS | -2 | -1 | -1 |
| Diluted EPS | -1.76 | -1.35 | -0.66 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 245.00M | 251.40M | 258.94M | 267.73M | 252.54M | 264.16M |
| Gross profit | 36.60M | 39.14M | 39.71M | 42.12M | 34.78M | 38.88M |
| Selling & admin expenses | 17.49M | 18.69M | 17.08M | 37.19M | 20.34M | 24.40M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 10.06M | 11.17M | 12.97M | -7.47M | 4.53M | 4.40M |
| Pretax profit | -4.31M | -2.42M | -237.00K | -25.26M | 3.08M | 5.77M |
| Tax | 3.38M | 4.81M | 3.26M | 3.43M | 1.36M | 3.02M |
| Net profit | -7.69M | -7.23M | -3.50M | -28.69M | 1.72M | 2.75M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.08 | -0.08 | -0.04 | -0.38 | 0.02 | 0.03 |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 166.77M | 172.52M | 227.26M |
| Cash & ST investments | 20.19M | 26.13M | 58.83M |
| Inventory | -- | -- | -- |
| Total assets | 1.67B | 1.67B | 1.76B |
| Total current liabilities | 161.12M | 173.66M | 179.19M |
| Short-term debt | 37.18M | 35.32M | 38.78M |
| Long-term debt | 1.18B | 1.19B | 819.03M |
| Total liabilities | 1,473,101,000.00 | 1,508,910,000.00 | 1,178,434,000.00 |
| Total equity | 198.43M | 161.65M | 586.12M |
| Retained earnings | -489.86M | -583.96M | -631.06M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 165.92M | 227.26M | 221.89M | 256.42M |
| Cash & ST investments | -- | -- | 191.00K | 58.83M | 51.23M | 69.71M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 1.69B | 1.76B | 1.76B | 1.81B |
| Total current liabilities | -- | -- | 179.99M | 179.19M | 157.93M | 178.36M |
| Short-term debt | -- | -- | 43.72M | 38.78M | 40.59M | 42.13M |
| Long-term debt | -- | -- | 1.18B | 819.03M | 816.97M | 819.75M |
| Total liabilities | -- | -- | 1,522,753,000.00 | 1,178,434,000.00 | 1,163,733,000.00 | 1,193,711,000.00 |
| Total equity | -- | -- | 167.11M | 586.12M | 599.62M | 615.06M |
| Retained earnings | -- | -- | -602.37M | -631.06M | -629.34M | -626.60M |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | 37.51M | 40.73M | 17.07M |
| Depreciation & amortization | 72.07M | 57.13M | 55.39M |
| Free cash flow | 13.51M | 12.95M | -6.40M |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | 2.14M | 673.00K | 435.59M |
| Ending cash balance | 20.19M | 26.13M | 58.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.96M | 2.07M | 11.86M | 17.10M | 2.93M | 32.80M |
| Depreciation & amortization | 12.79M | 12.96M | 13.39M | 16.24M | 13.88M | 14.08M |
| Free cash flow | -14.96M | -2.53M | -1.77M | 12.85M | -2.38M | 22.53M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 660.00K | 55.00K | 120.00K | 434.75M | 0 | -332.00K |
| Ending cash balance | 7.30M | 4.75M | 191.00K | 58.83M | 51.23M | 69.71M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | -61.60 | -52.27 | -12.60 |
| ROA %i | -7.31 | -5.63 | -2.74 |
| ROIC %i | -1.13 | 0.48 | 2.72 |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | 2.40 | 5.99 | 8.44 |
| FCF / sales %i | 1.44 | 1.37 | -- |
| Current ratioi | 1.04 | 0.99 | 1.27 |
| Quick ratioi | 0.93 | 0.93 | 1.17 |
| Debt / assetsi | 78.06 | 78.37 | 54.55 |
| LT debt / equityi | 638.80 | 788.07 | 157.60 |
| Interest coveragei | 0.16 | 0.42 | 0.73 |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -26.01 | -12.60 | -6.29 | -4.51 |
| ROA %i | -- | -- | -2.57 | -2.74 | -2.14 | -1.53 |
| ROIC %i | -- | -- | 3.19 | 2.72 | 1.62 | 1.70 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | 9.86 | 8.44 | 7.78 | 7.14 |
| FCF / sales %i | -- | -- | 0.02 | -- | 0.60 | 2.99 |
| Current ratioi | -- | -- | 0.92 | 1.27 | 1.40 | 1.44 |
| Quick ratioi | -- | -- | 0.83 | 1.17 | 1.30 | 1.36 |
| Debt / assetsi | -- | -- | 77.76 | 54.55 | 54.86 | 53.92 |
| LT debt / equityi | -- | -- | 760.14 | 157.60 | 154.57 | 151.73 |
| Interest coveragei | -- | -- | 0.81 | 0.73 | 0.76 | 0.82 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Outpatient is the largest reported line at 74.28% of revenue, across 3 reported segments.
- The next-largest line, Professional, is a distant second at 27.35% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Outpatient74.28%
Professional27.35%
Quote time 2026-10-08 09:55:13 · For reference only, not investment advice and not tailored to your situation.